tresk

Sipatrigine (619C89) is an antiepileptic compound with neuroprotective activity through glutamate release, TREK ion channels, TRESK channels, sodium channels, and calcium channel inhibitors in the CNS, and can be used to study TRESK channels.

A2793 is a dual inhibitor of TWIK-associated acid-sensitive K+ channel 1 (TASK-1) TRESK, with an IC50 for mTRESK of 6.8 μM. It is more selective for TRESK, and relatively weaker for TREK-1 and TALK-1.

DCPIB, a known specific and potent inhibitor of volume-regulated anion channels (VRAC),DCPIB displayed superior selectivity toward TRESK with an IC50 of 0.14 μM, demonstrating at least 100-fold higher affinity over TREK1 TRAAK channels.

ONO-2920632 is an orally active and CNS-penetrant TREK channel activator with EC50 values of 0.3 µM for TREK-1 and 2.8 µM for TREK-2. It demonstrates selectivity for other K2P channels, showing over 91-fold selectivity against TASK1, TASK2, TASK3, TRAAK, TWIK2, and 31-fold selectivity against TRESK. ONO-2920632 exhibits analgesic effects and is used in the study of pain, migraine, and neurological disorders.

A1899 is a effective and selective TASK-1 and TASK-3 antagonist.

A2764 dihydrochloride is a highly selective inhibitor of TWIK-related spinal cord K+ channel (TRESK).